1083 patents
Page 2 of 55
Design
Handheld drug delivery device
2 Jan 24
Matias Melander, Bjarke Lykke Ludvig Svendsen, Christian Plambech, Dylan Bourelle, Jakob Halkjaer Pedersen, Joshua J. Dudman, Emil Gram Spork
Filed: 29 Jul 22
Utility
C-terminal anti-sclerostin antibody variants
2 Jan 24
The invention generally relates to anti-sclerostin antibodies having C-terminal modifications, and compositions comprising such antibodies.
Zhe Huang, Jennitte LeAnn Stevens, Greg Flynn, Szilan Fodor, Mark Daris
Filed: 23 Sep 22
Utility
IL-17 receptor A antigen binding proteins
2 Jan 24
The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands.
Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
Filed: 5 Aug 20
Utility
In-process Verification of Calibration Status of PH Probes
28 Dec 23
Automated systems and methods for low-pH viral inactivation include adding an elution pool to a first vessel with an acid.
Venkatesh Natarajan, Marco DeLiso, Jeremy Aaron Bezaire, Andrew Cavigli, Jeremy S. Conner, Jon Hunter, Sidney Pehrson, Sarah Whetstone
Filed: 9 Nov 21
Utility
Methods for Decreasing Mortality Risk and Improving Health
28 Dec 23
The disclosure provides methods for decreasing mortality risk and/or improving health in a subject.
Kári Stefánsson, Daniel Gudbjartsson, Magnús Úlfarsson, Thjodbjorg Eiriksdottir
Filed: 15 Nov 21
Utility
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
21 Dec 23
The present invention relates to methods for treating or preventing atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a), a component of Lp(a) particles.
Winnie SOHN, Zachary JONES, Helina KASSAHUN
Filed: 4 Nov 21
Utility
Gas Permeable Sealing Member for Drug Container and Methods of Assembly
21 Dec 23
Drug delivery devices, sealing members for containers housed within such drug delivery devices, and related methods of assembly are disclosed.
Cheng-Chieh Chou, Mingda Eu, Ren-Yo Forng, Wael Mismar
Filed: 28 Apr 23
Utility
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 And/or PD-L1 Inhibitor
21 Dec 23
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.
James J. CAMPBELL, Rajinder SINGH, Jeffrey K. HARRISON
Filed: 3 May 23
Utility
Heterocyclic Spiro Compounds and Methods of Use
21 Dec 23
BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, MATTHEW R. KALLER, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M. MEDINA, ALEXANDER J. PICKRELL, NURIA A. TAMAYO, KAI ZHU
Filed: 26 Oct 21
Utility
Polypeptide Constructs Binding to CD3
21 Dec 23
The invention relates to a polypeptide or polypeptide construct comprising: a binding domain binding to an extracellular epitope of the human CD3s chain comprising or consisting of a VH region and a VL region, wherein i) the VH region comprises: a CDR-H1 sequence of X1YAX2N, where X1 is K, V, S, G, R, T, or I; and X2 is M or I; a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2, where X1 is S or Q; and X2 is D, G, K, S, or E; and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY, where X1 is G, R, or A; X2 is I, L, V, or T; X3 is Y, W or F; and X4 is W, F or Y; and ii) wherein the VL region comprises: a CDR-L1 sequence of X1 SSTGAVTX2X3X4YX5N, where X1 is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y and X5 is P or A; a CDR-L2 sequence of X1TX2X3X4X5X6; where X1 is G or A; X2 is K, D, or N; X3 is F, M or K; X4 is L or R; X5 is A, P, or V; and X6 is P or S; and a CDR-L3 sequence of X1LWYSNX2VW, where X1 is V, A, or T; and X2 is R or L; and iii) wherein one or more of CDR sequences of the VH region of i) and/or of the VL region of ii) comprise one amino acid substitution or a combination thereof selected from X24V and X24F in CDR-H1; D15, and X116A in CDR-H2; H1, X12E, F4, and N6 in CDR-H3; and X11L and W3 in CDR-L3.
Doris Rau, Tobias Raum, Partrick Hoffmann, Markus Muenz, Matthias Klinger, Virginie Naegele, Lisa Winkel, Pavan Ghattyvenkatakrishna, Joon Hoi Huh, Arnold McAuley, Sekhar Kanapuram
Filed: 8 Nov 21
Utility
Methods of treating hidradenitis suppurativa
19 Dec 23
Shijie Li, Rajinder Singh, Thomas J. Schall, Peter Staehr
Filed: 27 Oct 21
Utility
Processes and intermediates in the preparation of C5aR antagonists
19 Dec 23
Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
Filed: 8 Feb 22
Utility
PRMT5 inhibitors
19 Dec 23
Shon Booker, Matthew Paul Bourbeau, John R. Butler, Sanne Ormholt Schroder Glad, Brian Alan Lanman, Patricia Lopez, Francesco Manoni, Liping H. Pettus, Ian Sarvary, Nuria A. Tamayo, Mikkel Vestergaard, Nicholas Anthony Weires
Filed: 15 Dec 21
Utility
Methods for Administering Therapeutic Doses of Bispecific T-cell Engaging Molecules for the Treatment of Cancer
14 Dec 23
The present invention relates to methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer in a patient.
Adam B. MCCULLOUGH, Hosein KOUROS-MEHR, Peter KUFER, Mark SALVATI, Alexander C. MINELLA, Dirk NAGORSEN, Vijay UPRETI, Mukul MINOCHA, Brett HOUK
Filed: 15 Sep 21
Utility
Robotic System for Performing Pattern Recognition-based Inspection of Pharmaceutical Containers
14 Dec 23
A robotic inspection platform comprises a robotic arm, an imager, and a controller.
Dmitry Fradkin, Thomas Clark Pearson, Neelima Chavali, Erwin Freund
Filed: 18 Aug 23
Utility
Titration Methods for Detecting Polyvinyl Sulfonate (PVS) In Buffers
14 Dec 23
The disclosure provides methods, including automated methods, to detect levels of polyanions such as polyvinyl sulfonates in fluids such as buffers by complexometric or titration-based techniques.
Robert Joseph Soto
Filed: 15 Oct 21
Utility
Nucleic acid biomarker and use thereof
12 Dec 23
The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high.
Matthias Schneider, Sabine Blum, Renee Jeanne Mendell-Harary, Daniel J. Freeman, Robert Allen Beckman, Xiaoping Jin
Filed: 21 Aug 19
Utility
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
12 Dec 23
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
Filed: 24 Jun 21
Utility
Process for Racemizing and Isolating Atropisomers of 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE
7 Dec 23
Matthew G. BEAVER, Michael T. CORBETT, Yuanqing FANG, David D. FORD, Andrew T. PARSONS, Gabrielle ST-PIERRE, Reem TELMESANI
Filed: 6 Oct 21
Utility
CXCR7 antagonists
5 Dec 23
Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
Filed: 27 May 21